Konstantinos Lontos

8PUBLICATIONS
25CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cellular immunologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 24, 2025
TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation.

Konstantinos Lontos, Rima M Saliba, Rashmi Kanagal-Shamanna

|Aug 08, 2023
An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment.

Kristin DePeaux, Dayana B Rivadeneira, Konstantinos Lontos

|Feb 01, 2023
Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy.

Konstantinos Lontos, Anastasia Tsagianni, Mounzer Agha

|Dec 21, 2022
Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity.

Paolo D A Vignali, Kristin DePeaux, McLane J Watson

|Sep 08, 2022
A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML.

Konstantinos Lontos, Anastasia Tsagianni, Mounzer Agha

Pageof 2